- HDSA Research
- Grant Applications
- Research News & Reports
- Research Webinar Series
- Kids-HD: Brain Imaging Research Study
- Omeros PDE10 inhibitor (OMS-643762) trial
- Presymtomatic Testing for HD
- Survey: The role of genetic counselors
- What Are Clinical Trials
- Find the Clinical Trials In Your Area
- International Enroll-HD Sites
- Clinical Trials Diplomats
- HDBuzz Research News
- HD Gene Symposium: 20 Years
- Therapies in Pipeline
- Research Conferences
- Scientific Advisory Board
- Research Pipeline
- Stem Cells
- HD Insights
- HD Glossary
- Links to Other Research
- Reports Library
- Research Investors Reports
2CARE - Coenzyme Q10 in Huntington's Disease
Drs. Merit Cudkowicz (Massachusetts General Hospital), Michael McDermott (University of Rochester) and Karl Kieburtz (University of Rochester) of the Huntington Study Group (HSG) are conducting a multi-center, randomized, double-blind, placebo-controlled study of coenzyme Q10 (CoQ10) in individuals with Huntington disease (HD) to assess the effects of CoQ on the progression of functional decline in HD, as well as the long-term safety and tolerability at the dosage studied. Coenzyme Q10, a naturally occurring substance in the body, is available for purchase over the counter as a nutritional supplement -- this study is evaluating its effectiveness at a much higher dosage than is currently available.
CoQ10 has been used to treat a variety of human disorders, including those involving the heart and circulatory system, cancer, muscular dystrophy, a muscle coordination disorder called ataxia, and other disorders. The most marked results seem to have occurred in patients with a preexisting inherited deficiency of CoQ10, although the studies reporting this information are limited by their not being controlled clinical trials. Recent preliminary studies of CoQ10 in neurologic disorders such as Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's Disease confirm the safety and tolerability of CoQ10 in daily dosages up to, including, and exceeding the dosage planned for the 2CARE study when used for a short time.
The 2CARE study will be the largest therapeutic clinical trial to date in Huntington's Disease. Six hundred eight research participants will be enrolled at approximately forty-six clinical sites in the US, Canada, and Australia.
For: Gene-positive individuals over 16 years old with a TFC of more than 9. Click here for more information and exclusion criteria.